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The inflammatory gene response requires activation
of the protein kinase TAK1, but it is currently un-
known how TAK1-derived signals coordinate tran-
scriptional programs in the genome. We determined
the genome-wide binding of the TAK1-controlled
NF-kB subunit p65 in relation to active enhancers
and promoters of transcribed genes by chromatin
immunoprecipitation sequencing (ChIP-seq) ex-
periments. Out of 35,000 active enhancer regions,
410 H3K4me1-positive enhancers show interleukin
1 (IL-1)-induced H3K27ac and p65 binding. Inhibition
of TAK1 or IKK2 or depletion of p65 blocked inducible
enhancer activation and gene expression. As exem-
plified by the CXC chemokine cluster located on
chromosome 4, the TAK1-p65 pathway also regu-
lates the recruitment kinetics of the histone acetyl-
transferase CBP, of NF-kB p50, and of AP-1 tran-
scription factors to both promoters and enhancers.
This study provides a high-resolution view of epige-
netic changes occurring during the IL-1 response
and allows the genome-wide identification of a dis-
tinct class of inducible p65 NF-kB-dependent en-
hancers in epithelial cells.INTRODUCTION
Interleukin 1 (IL-1) is a prototypic pleiotropic cytokine that
strongly induces local and systemic inflammation (Dinarello
et al., 2012). Evidence in humans shows that dysregulation of
IL-1 is sufficient to drive the entire systemic inflammatory
response, thus demonstrating that this cytokine is at the apex
of inflammatory cascades (Aksentijevich et al., 2009). At the
cellular level, the main effect of IL-1 is the rapid reprogramming
of inflammatory gene expression (Schmitz et al., 2011; Weber
et al., 2010).726 Cell Reports 10, 726–739, February 10, 2015 ª2015 The AuthorsA central regulator of this gene response in the cytoplasm is
the protein kinase TAK1, which is activated by proinflammatory
cytokines (IL-1, tumor necrosis factor [TNF]), transforming
growth factor-ß (TGF-ß), stressors, and by various toll-like re-
ceptors (TLRs) (Sakurai, 2012). One major role of TAK1 is to
phosphorylate mitogen-activated protein kinases (MAPKs),
which then activate individual p38 and JNK MAPK pathways
(Ninomiya-Tsuji et al., 1999). Hence, the kinase is upstream of
several transcription factors (TFs) such as Jun or ATF family
members, which are all substrates of MAPKs (Shaulian and
Karin, 2002). Also, the TF NF-kB is activated by TAK1-mediated
signals on a pathway involving TAK1-mediating activation of IkB
kinases (IKKs) (Sakurai et al., 1999). These, in turn, phosphory-
late the cytosolic inhibitor IkBa and enable its ubiquitin/protea-
some-dependent destruction, thus allowing nuclear transloca-
tion of NF-kB (Hayden and Ghosh, 2008). The NF-kB p65
subunit has the strongest transactivation potential and its activity
is also controlled by many posttranslational modifications
including IKK-mediated phosphorylation of the p65 C-terminal
transactivation domain at S536, thereby providing an additional
mechanism for fine-tuning NF-kB transcriptional activity (Per-
kins, 2012). Thus, TAK1 is an apical and global regulator of mul-
tiple AP-1 family members and of the NF-kB pathway, but the
consequences of TAK1 activity on nuclear events and chromatin
binding of TFs have not yet been defined.
Enhancers are gene regulatory elements that control the
activity of promoters independent from location, distance, or
orientation (Pennacchio et al., 2013). Enhancers are vital for
lineage determination and maintenance of cell types by orga-
nizing the recruitment of lineage-specific transcription factors,
which provide crucial control of cell-specific genes (Ghisletti
and Natoli, 2013). Accordingly, enhancers are characterized
by specific chromatin states and nucleosomal depletion. Re-
cent evidence shows that active enhancers are associated
with characteristic chromatin signatures, most importantly
H3K4me1, p300 acetyltransferase occupancy, and H3K27
acetylation (Flintoft, 2013). High-resolution studies of these
marks revealed that enhancers are highly abundant gene regu-
latory elements with recent estimates ranging from 25,000 to
several hundreds of thousands (Zhu et al., 2013; Shen et al.,
2012). Recent work in murine macrophages unraveled PU.1-
dependent lipopolysaccharide (LPS)-regulated enhancers, pro-
viding support for the dynamic nature of the enhancer reper-
toire in innate immune cells (Ostuni et al., 2013). Comparable
information on enhancer regulation by inflammatory cytokines,
which are vital executers of innate immune functions in most
tissues, is lacking.
Because the nuclear signaling network utilized by IL-1 is
largely unexplored, we analyzed IL-1-induced chromatin signa-
tures and TF binding at the genome-wide level. We identified
47,609 p65 peaks of which 1,264 were regulated by IL-1. The
majority of p65 recruitment occurred at intergenic regions of un-
known function. Additionally, we discovered 35,130 enhancers
including 1,575 IL-1-inducible enhancers. A subgroup of 410 en-
hancers shows IL-1-inducible H3K27ac and p65 recruitment and
is found upstream of cytokine-induced genes. The activation of
this type of IL-1-induced enhancers was fully dependent on
the kinase activity of TAK1 and IKK2 and on the presence of
NF-kB p65. The TAK1-p65 pathway also regulates the recruit-
ment kinetics of a number of AP-1 factors to both promoters
and enhancers. The concerted and synchronized activation of
IL-1-driven enhancers provides a unifying molecular mechanism
for the rapid and strong upregulation of inflammatory genes
evoked by this cytokine.
RESULTS
Identification of IL-1-Regulated Intergenic Enhancers
Flanking the CXCChemokine Cluster on Chromosome 4
To identify the number of IL-1-induced genes in epithelial cells,
KB cells were stimulated for various periods of timewith IL-1, fol-
lowed by the analysis of gene expression by microarrays. These
experiments showed the IL-1-inducible and time-dependent
mRNA expression of 241 genes (Figure S1A; Table S1) and
thus indicate that this cell line is well suited to study IL-1-depen-
dent transcription and chromatin regulation. To address the
question of which chromatin-based processes accompany IL-
1-induced and p65-dependent gene expression, we performed
chromatin immunoprecipitation sequencing (ChIP-seq) experi-
ments with antibodies recognizing the NF-kB p65 protein and
chromatin marks typical for active promoters or enhancers as
described above (H3K9ac, H3K4me1, and H3K27ac). In addi-
tion, genome-wide localization of IL-1-triggered transcripts and
ongoing transcription were determined by RNA sequencing
(RNA-seq), or by ChIP-seq using antibodies directed at RNA po-
lymerase II (Pol II) and by measuring the serine 5 phosphorylated
form of Pol II (P(S5)-Pol II), which occurs during transcription initi-
ation (Figure 1A).
For the analysis of ChIP-seq data, we initially focused on a
gene cluster containing the highly regulated chemokine genes
IL8 (CXCL8), CXCL1, 2, and 3 (Figure S1B). These chemokines
lie within a genomic region spanning 0.4 Mb of chromosome 4.
This region showed strongly regulated p65 binding immediately
upstream of the transcriptional start sites (TSSs) of IL8, CXCL1,
2, and 3, reflecting p65 recruitment to canonical NF-kB sites
within the promoters of these genes (Figure 1A, marked by
dotted boxes). In addition, we found strongly induced p65 peaks
located in two intergenic regions flanking the IL8 and CXCL2Cegenes (Figure 1A, marked by solid boxes). RNA-seq and Pol II
ChIP-seq analyses showed no signs of ongoing transcription
of these intergenic regions (Figure 1A). Repressive chromatin
marks such as H3K9me3 were absent, in agreement with the
biological need to immediately express these chemokine genes
in precarious situations. The histone mark H3K9ac was already
seen in unstimulated cells and IL-1 treatment augmented this
modification at all p65 sites (Figure 1A). Small peaks of basal
H3K27ac were found at the promoters of transcribed genes (Fig-
ure 1A, dotted boxes). Significantly stronger basal H3K27ac
marks were found in the regions surrounding the intergenic
p65 peaks (Figure 1A, solid boxes). After IL-1 stimulation of cells,
H3K27ac levels at these regions increased even further (Fig-
ure 1A, solid boxes). Small areas of basal H3K4me1 were found
at promoters (Figure 1A, dotted boxes), whereas very strong sig-
nals occurred at intergenic regions occupied by p65 (Figure 1A,
solid boxes). However, H3K4me1 marks were not regulated
by IL-1 (Figure 1A, solid boxes). In comparison, inspection of
an unrelated genomic region that did not contain IL-1-regulated
genes showed strong but comparable H3K9ac, H3K27ac, and
H3K4me1 signals as well as many nonregulated p65 peaks (Fig-
ure S2A). These data show that IL-1-induced gene regulation
involves a specific pattern of regulated chromatin marks in asso-
ciation with p65 binding whosemajor features are summarized in
Figure 1B. Moreover, these data suggest that IL-1 specifically
operates through a dual mechanism, which involves p65 binding
to individual gene promoters and additionally p65 association
with putative intergenic enhancers marked by strong H3K4me1
and regulated H3K27ac signals flanking clusters of highly core-
gulated genes.
High-Resolution Mapping of Intergenic and
TSS-Associated p65 NF-kB Binding Sites
To find out whether the patterns of p65 binding and chromatin
modifications described above are restricted to the particularly
strongly regulated chemokine locus on chromosome 4 or
whether they also occur for other IL-1-regulated genes, we
further analyzed the nuclear and genomic distribution of p65.
In KB cells, about 15%–20% of total p65 protein is present
constitutively within the nucleus whereby the insoluble fraction
(N2) that is stably associated with chromatin accounts for only
about 5% (Figure 2A). In line with its capacity to activate the ca-
nonical TAK1-IKK2-NF-kB pathway, IL-1 treatment strongly
increased the amount of p65 in both the soluble (36%) and the
insoluble (15%) fractions resulting in a redistribution of about
50% of total p65 to the nucleus within 1 hr of cytokine exposure
(Figure 2A). IL-1 also induced phosphorylation of p65 at S536
and nuclear translocation of the p50 subunit indicating that the
cytokine controls NF-kB signaling to chromatin through multiple
steps (Figure 2A). To get further insight into the mechanisms
operating downstream of nuclear translocation of p65, the
ChIP-seq data sets were analyzed at the genome-wide level. In
total, we identified 47,609 distinct p65 peaks. Constitutive p65
binding occurred at 46,345 genomic locations, whereas 1,264
p65 peaks were regulated by IL-1 by at least 2-fold (Figure 2B).
Compared to those sites showing constitutive binding, IL-1-
inducible peaks were characterized by much lower basal chro-
matin binding and increased recruitment after inductionll Reports 10, 726–739, February 10, 2015 ª2015 The Authors 727
Figure 1. Identification of IL-1-Regulated Intergenic Enhancers Flanking the CXC Chemokine Cluster Located at Chromosome 4
(A) Human epithelial KB cells were stimulated with IL-1 for 1 hr or were left untreated. Then chromatin or total RNA was prepared, and RNA-seq or ChIP-seq
experiments were performed using the indicated antibodies, and read coveragewas determined. Shown are coverage profiles across the humanCXC chemokine
(legend continued on next page)
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Figure 2. Genome-wide Identification and
Location of p65 Binding Sites and Their
Correlation with Histone Modifications
(A) KB cells were stimulated with IL-1 for 1 hr or
were left untreated. Then, cytosolic (C), soluble
(N1), and insoluble (N2) nuclear extracts were
prepared and examined for the presence of the
indicated proteins and their phosphorylation
status by immunoblotting using the indicated
antibodies. Numbers underneath the p65 panel
indicate the relative amount of p65 in each fraction
compared to content of total p65 protein in un-
stimulated cells (calculated as the sum of p65 in
C + N1 + N2). Antibodies against b-actin, tubulin,
or phosphorylated RNA Pol II served as controls
for equal loading and purity of the subcellular
fractions. The relative positions of molecular
weight markers are indicated.
(B) ChIP-seq datawere used to calculate the signal
intensities of p65 peaks and to identify 46,345
constitutive p65 peaks (gray boxes) and 1,264 p65
peaks, which were regulated by IL-1 (green
boxes).
(C) Pie charts showing the positions of constitutive
versus IL-1-regulated p65 peaks relative to the
transcriptional start sites (TSSs) of the next anno-
tated protein-coding genes.
(D) ChIP-seq data were used to calculate the
overlap signals of constitutive versus IL-1-regu-
lated p65 peaks with the indicated histone modi-
fications.
See Table S3 for statistics for Figures 2B and 2D.
See also Figure S2.(Figure 2B). About 50% of all constitutive binding sites and
almost 75% of all IL-1-inducible sites were located >20 kb up-
stream of the next annotated gene (Figure 2C). Only 2.93%
(728 of 24,828 sites) of all p65 peaks located >20 kb upstream
of the next TSS were overlapping with Pol II and P(S5)-Pol II
peaks, whereas 76% (7,405 of 9,744 sites) of all peaks located
between –0.5 kb and the TSS were associated with Pol II and
P(S5)-Pol II peaks (Figure S2B). These data show that p65 peaks
found close to TSS are associated with actively transcribed
genes, whereas intergenic p65 peaks may have an alternative
function (Figure S2B). At the genome-wide level, regions encom-
passing basal or IL-1-inducible p65 sites were usually associ-
ated with H3K9me3, H3K9ac, H3K4me1, and H3K27ac marks
(Figure 2D). Therewas no change of all fourmarks after IL-1 stim-locus on chromosome 4. Black dotted frames indicate positions of promoters/transcribed genes. Black s
enhancer regions flanking the IL8 and CXCL2 loci. The top shows a schematic representation of the exons
(B) Summary of basal and IL-1-regulated chromatin changes within the CXC chemokine cluster.
See also Figures S1 and S2 and Table S1.
Cell Reports 10, 726–739,ulation within the group of constitutive
p65 peaks (Figure 2D, gray boxes).
However, IL-1-inducible peaks showed
reduced H3K9me3 levels independent of
IL-1 and an increase of H3K9ac only after
IL-1 stimulation (Figure 2D, green boxes).
In contrast, across all IL-1-inducible p65peaks, median H3K4me1 and H3K27ac levels were elevated,
whereby H3K4me1 was not regulated by IL-1 and H3K27ac
further increased after cytokine treatment (Figure 2D, green
bars). These data suggest that the about 50,000 p65 peaks
found at the genome-wide level are either associated with active
enhancers or lie directly adjacent to active genes. Moreover,
based on their recruitment patterns and the accompanying chro-
matin modifications they can be divided into two distinct groups:
a large, constitutive group of 46,345 peaks and a highly dynam-
ically regulated group of 1,264 p65 binding regions character-
ized by altered basal and IL-1-inducible p65 recruitment
and accompanying histone modifications, suggesting that these
chromatin regions confer specific features of cytokine-mediated
gene regulation.olid frames indicate positions of two p65-binding
of all transcribed and nontranscribed genes.
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Figure 3. Genome-wide Identification of IL-1-Regulated Enhancers
(A) Schematic display of three types of active enhancers identified in KB cells by parallel occurrence of H3K4me1 and H3K27ac marks. The 46 class I and 410
class II enhancers differ by their IL-1-mediated regulation of H3K4me1 or H3K27ac, respectively, and by the additional presence of p65 binding sites.
(B and C) ChIP-seq data were used to calculate the signals for IL-1-regulated enhancers (B) or for the class I and class II enhancers (C). Numbers in brackets
indicate the total number of p65 peaks detected in class I or class II enhancers (C).
(D) The mean regulation of gene expression by IL-1 for all genes and for genes next to the 410 class II enhancers is shown. Data were calculated frommicroarray
data (p = 1.29 3 1024) and from RNA-seq experiments (p = 1.51 3 1017).
(E) De novo motif searches and correlation with known motifs for all 410 class II enhancers.
(legend continued on next page)
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Genome-wide Identification of IL-1- and p65-Regulated
Enhancers
Because most p65 peaks were far away from the next gene, we
then thought to further characterize the p65 associated enhancer
repertoire. High-resolution mapping across all conditions (basal
and IL-1-stimulated) revealed 48,133 H3K27ac and 70,225
H3K4me1 peaks. From these data, we derived 35,130 regions
as active enhancers, as defined by the presence of both
H3K27ac and H3K4me1 marks (Figure 3A). IL-1 did not affect
both marks simultaneously but did enhance histone marks
individually. Specifically, we found 468 DNA regions showing
IL-1-inducible H3K4me1 and 1,107 regions showing inducible
H3K27ac (Figures 3A and 3B). Forty-six out of the 468 active en-
hancers were associated with p65 peaks, and we designated
them as regulated class I enhancers (Figures 3A and 3C). Of
the 1,107 enhancers, 410 were associated with 469 p65 peaks
andwere called class II enhancers (Figures 3A and 3C). The class
II enhancers showed low basal but highly IL-1-inducible p65
recruitment and thus most closely resembled the enhancer re-
gions associated with the chemokine cluster shown in Figure 1
(Figure 3C). We therefore focused all further analysis on this
subgroup of 410 IL-1-responsive enhancers. Compared to all ex-
pressed genes within the data set, the genes next to class II en-
hancers were regulated by IL-1 as assessed from our microarray
and RNA-seq data sets (Figure 3D). Motif searches revealed that
class II enhancerswere enriched for binding sites for NF-kB, Elf3/
5, FEV, STAT3, SPI1, Jundm2, GCN4, and Fos (Figure 3E). Meta-
profiles of the class II enhancers showed that basal and inducible
H3K27ac was strongly enriched and was peaking symmetrically
at regions immediately adjacent to inducible p65 binding sites
(Figure 3F). Regions of p65 binding showed dips of H3K27ac
and H3K4me1 marks, indicating the reduction in nucleosome
density after p65 recruitment (Figure 3F). H3K27ac enhancer
marks covered larger genomic regions after IL-1 stimulation,
either due to reduced chromatin compaction or to increased
spreading of histone modifications. In unstimulated cells the
410 class II enhancers extended from 400 to 1,500 bp (median
of 644 bp), whereas IL-1 stimulation resulted in a further increase
in median enhancer width to 1,109 bp (Figure 3G). Collectively,
the data shown in Figures 2 and 3 identify a class of several hun-
dred cytokine-inducible enhancers that are located upstream
of the majority of all IL-1-regulated genes. Moreover, the data
suggest that p65, in addition to its classical role in activating
promoter-dependent transcription, plays a prominent role in
the formation or regulation of these enhancer structures.
Genome-wide Regulation of IL-1-Inducible Enhancers
by a TAK1-IKK2-Dependent Pathway
To identify the upstream signals involved in gene- and enhancer-
specific recruitment of p65 NF-kB, a central part of the IL-1-
triggered signals was blocked by the cell-permeable ATP-
competitive kinase inhibitor 5Z-7-oxozeaenol. This compound
covalently binds to C174 within the ATP-binding pocket of(F) p65 peaks of all 410 class II enhancers were centered and meta-profiles for H3
cells across 8 kb of adjacent genomic sequences.
(G) The distribution of enhancer widths of untreated and IL-1-induced class II en
See Table S3 for statistics for Figures 3B and 3C.
CeTAK1, allowing fast inhibition of TAK1 enzymatic activity in
cultured cells (Wu et al., 2013). 5Z-7-oxozeaenol blocked the
vast majority of IL-1-inducible genes (Figure S3A; Table S2).
The inhibitory effect on gene expression was almost complete,
as exemplified by heatmaps of the top-ranking IL-1-regulated
genes (Figure S3B) and shown in Table S2. At the global chro-
matin level, 5Z-7-oxozeaenol affected only the recruitment of
the IL-1-inducible group, but not the constitutive group of p65
peaks (Figure S3C). In line with this result, 5Z-7-oxozeaenol sup-
pressed IL-1-inducible IkBa phosphorylation as well as the
inducible p65 nuclear translocation and S536 phosphorylation
(Figures S4A and S4B, top). Accordingly, 5Z-7-oxozeaenol
completely inhibited IL-1-inducible IL8 and CXCL2 mRNA
expression, demonstrating the relevance of the TAK1 pathway
for the regulation of the CXC chemokine locus (Figure S4C).
Additionally, TAK1 controls further MAPK signaling. Thus, 5Z-
7-oxozeaenol also suppressed inducible phosphorylation of
JNK, p38, and c-Jun and the expression of c-Jun and c-Fos in
a dose- and time-dependent manner (Figures S4D and S4E). Un-
der these conditions, little effect of 5Z-7-oxozeaenol was seen
on protein levels of ATF2, JunD, and JunB (Figures S4D and
S4E). 5Z-7-oxozeaenol also inhibited autophosphorylation of
TAK1 (Figures S4D and S4E), further indicating its specificity
and suitability for suppression of TAK1-mediated signaling in hu-
man KB cells. ChIP-seq profiles illustrate that 5Z-7-oxozeaenol
suppressed IL-1-inducible p65 recruitment, Pol II loading, and
Pol II S5 phosphorylation and H3K27ac at all regions of the IL8
and CXCL2 loci, whereas no effects on H3K4me1 were seen
(Figure 4A). Moreover, 5Z-7-oxozeaenol inhibited IL-1-inducible
p65 recruitment and H3K27ac across the 410 class II enhancers
but had no effect on all 35,130 enhancers (Figure 4B). Because
TAK1 is an upstream regulator of IKK2 (Zhang et al., 2014), it
was interesting to test the consequences of IKK2 inhibition for
IL-1-induced global p65-dependent enhancer activation. The
specific IKK2 inhibitor PHA-408 (Mbalaviele et al., 2009) inhibited
IL-1-inducible IkBa phosphorylation and IL8 and CXCL2 mRNA
induction in both HeLa cells (data not shown) and KB cells (Fig-
ure 4C). Similar to 5Z-7-oxozeaenol, the compound inhibited
inducible phosphorylation and nuclear translocation of p65 (Fig-
ures S4A and S4B, bottom). Under these conditions, PHA-408
suppressed inducible H3K27ac across the 410 class enhancers
(Figure 4D). Collectively, these data therefore suggest that a
TAK1-IKK2 pathway plays a direct and specific role in IL-1-
inducible enhancer activation.
Identification of p65 as a Cytokine-Inducible Priming
Factor for Enhancer Activation Downstream of TAK1
and IKK2
These results raised the question whether, downstream of
TAK1 and IKK2, p65 recruitment was a cause or consequence
of enhancer activation. Small hairpin RNA (shRNA)-mediated
depletion of p65 in HeLa cells, which are closely related to KB
cells, prevented IL-1-induced expression of IL8 and CXCL2, theK27ac and H3K4me1 were compiled from IL-1-treated cells or from untreated
hancers was calculated (p = 0.002).
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Figure 4. The Activation of IL-1-Regulated
Enhancers Is TAK1 and IKK2 Dependent
(A) KB cells were left untreated or were treated for
30 min with the TAK1 inhibitor 5Z-7-oxozeaenol
(5Z, 1 mM), with IL-1 for 1 hr or with 5Z-7-ox-
ozeaenol followed by IL-1 (IL-1 + 5Z). Then
ChIP-seq experiments were performed using the
antibodies shown in Figure 1. Profiles for the IL8
and CXCL2 loci are shown; yellow colors indicate
samples from cells treated with 5Z-7-oxozeaenol.
The presence of NF-kB motifs is indicated by
vertical lines underneath the p65 panels. Gray or
blue bars indicate genomic areas comprising
H3K4me1 and H3K27ac-positive enhancers or
class II enhancers, respectively.
(B) The mean signal intensities of p65 binding and
histone modifications for all 35,130 enhancers
versus all 410 class II enhancers were calculated
for all conditions described in (A).
(C) KB cells were treated for the indicated times
with the IKK2 inhibitor PHA-408 (5 mM) or with IL-1
in the indicated combinations. Top: the suppres-
sive effects of PHA-408 on IKK activity and IkBa
breakdown were assessed by immunoblotting of
whole-cell extracts using antibodies against the
phosphorylated and unphosphorylated forms of
IkBa. b-actin amounts were determined to control
for equal loading. Bottom: in parallel, cells were
treated with IL-1 for 1 hr or with PHA-408 (5 mM) as
indicated and mRNA expression of IL8 or CXCL2
was quantified by RT-qPCR. Shown is the mean
fold regulation ± SEM from three independent
experiments.
(D) KB cells were treated with vehicle (, DMSO),
IL-1 for 1 hr, or PHA-408 (PH, 5 mM) or combina-
tions of IL-1 and PHA-408 as indicated, and ChIP-
seq experiments were performed and analyzed as
described in (B) using antibodies against H3K27ac.
See Table S3 for statistics for Figures 4B and 4D.
See also Figures S3 and S4 and Table S2.two genes flanking the chemokine cluster on chromosome4 (Fig-
ure 5A). Based on theChIP-seqprofiles,we thendesignedprimer
pairs to accurately cover the IL8 and CXCL2 flanking enhancers
and promoters as well as negative control regions of both genes
as shown schematically in Figure 5B. Three enhancer primer
pairs per gene were used to detect the p65 peak or the adjacent732 Cell Reports 10, 726–739, February 10, 2015 ª2015 The AuthorsmaximaofH3K27acorH3K4me1.Quanti-
tative ChIP-PCR experiments were per-
formed to determine p65 recruitment,
deposition of constitutive and IL-1-induc-
ible H3K27ac and H3K4me1 histone
marks, histone H3 density, and Pol II
recruitment at the enhancers and pro-
moters of IL8 and CXCL2 (Figure 5C,
top). Depletion of p65 not only resulted in
the absence of enhancer and promoter
recruitment of this factor, but also pre-
vented RNA Pol II loading (Figure 5C,
top). Moreover, basal and IL-1-inducible
H3K27 acetylation was strongly impairedin the absence of p65, whereas H3K4me1 remained largely un-
changed (Figure 5C, top). IL-1 treatment also resulted in a reduc-
tion of H3 density at the IL8 and CXCL2 promoters, which is an
indication of reduced chromatin compaction (Figure 5C, top).
Suppression of p65 counteracted IL-1 triggered chromatin de-
compaction (Figure 5C, top), indicating that p65 is controlling
Figure 5. Essential Role of the NF-kB p65 Pathway in Enhancer Acetylation and Transcription of CXC Chemokine Genes
(A) HeLa cells were transfected with a plasmid vector directing the expression of a shRNA targeting p65 (shp65) or with empty pSuper-Puro. After 2 day selection
in puromycin, cells were stimulated with IL-1 for 1 hr or were left untreated. Protein expression of p65 was examined by immunoblots (top) andmRNA expression
of IL8, CXCL2, and RELA (p65) by RT-qPCR (bottom). Shown are mean fold changes ±SEM from two independent experiments performed in duplicates.
(B) Zoomed-in ChIP-seq profiles for IL-1 regulated chromatinmodifications at H3K27ac andH3K4me1 aswell as for p65 binding of the IL8 andCXCL2 loci. NF-kB
motifs, enhancer regions, and class II enhancers are shown by vertical lines or gray or blue bars, respectively. Numbers 1–10 and black bars indicate six enhancer
regions, two promoter regions, and two negative control regions, which were analyzed in detail by subsequent quantitative ChIP-PCRs.
(C) Top: vector-transfected or p65 knockdown cells were stimulated for 1 hr with IL-1 or were left untreated. ChIP experiments across the enhancers (primer pairs,
1, 2, 3 for IL8 and 8, 9, 10 forCXCL2) or promoters (primer pairs 5 and 6) or negative control regions (primer pairs 4 and 7) as shown in (B) were performed using the
indicated antibodies. Bottom: the same analysis was performed using chromatin from KB cells treated with vehicle (DMSO), PHA-408 (5 mM), or IL-1 (1 hr) in the
indicated combinations. Shown are the mean values (% input) ±SEM from at least two independent experiments performed in duplicates.
See also Figures S4, S5, and S6.not only histonemodifications, but also nucleosome density. The
relevance of p65 for inducible H3K27ac was also seen for other
arbitrarily selected class II enhancers (Figures S5A and S5B),
showing the general contribution of this transcription factor forCeIL-1-regulated H3K27ac. By qPCR, the importance of IKK2 and
TAK1 for IL-1-induced p65 recruitment and H3K27ac at the IL8
and CXCL2 loci was also revealed in KB cells pretreated either
with PHA-408 (Figure 5C, bottom) or 5Z-7-oxozeaenolll Reports 10, 726–739, February 10, 2015 ª2015 The Authors 733
Figure 6. Kinetics and TAK1-Dependent Recruitment of p65 and AP-1 Factors to IL-1-Inducible Enhancers and Promoters
(A and B) KB cells were stimulated for the indicated times with IL-1 or were left untreated. ChIP-PCR experiments were performed using the indicated antibodies
with primers covering the promoter or enhancer regions of the IL8 locus (A) or the CXCL2 locus (B) as schematically shown in Figure 5B.
(C and D) KB cells were treated for 30 min with the TAK1 inhibitor 5Z-7-oxozeaenol (1 mM) or with IL-1 for 1 hr at the indicated combinations. ChIP experiments
were performed as in (A) and (B). The bars show the mean enrichment (% input) ±SEM from at least two experiments performed in duplicates.
See also Figures S4 and S7.(Figure S6A). The critical contribution of TAK1 to inducible p65
binding, H3K27ac, and chemokine gene expression was
confirmed in an independent experimental approach after
shRNA-mediated downregulation of TAK1 expression (Figures734 Cell Reports 10, 726–739, February 10, 2015 ª2015 The AuthorsS6B and S6C). Collectively, the results displayed in Figures 4
and 5 show how the TAK1-IKK2-p65 pathway relays cytosolic
signals to chromatin modifications in order to mediate coordi-
nated enhancer and promoter activation of IL-1 target genes.
The TAK1-p65 Pathway Primes and Coordinates
Recruitment of Additional Factors at IL-1-Inducible
Enhancers and Promoters
We then thought to unravel the kinetics of proteins assembling in
addition to p65 at enhancers and promoters of the IL8 and
CXCL2 loci downstream of TAK1 in more detail. We determined
the recruitment kinetics of the TFs c-Fos, JunD, c-Jun, ATF2,
and FRA1 that are known to recognize AP-1 sites as those found
by the motif searches and of the histone acetyl transferase
cofactor CBP. Several of these factors had already been impli-
cated in IL8 or CXCL2 gene regulation (Hoffmann et al., 2005).
All TFs and CBP bound to IL8 and CXCL2 at promoters but
also to the enhancers (Figures 6A and 6B). These recruitments
were specific according to the low signals in immunoglobulin G
controls (Figures 6A and 6B) and to lack of binding of any of these
factors to the negative control region upstream of the IL8 pro-
moter (Figures S7A and S7B), which as shown in Figure 5B lacks
H3K27ac and H3K4me1 histone modifications. According to
their kinetics of recruitment, we assigned these factors to three
groups. Group 1 comprises p65, c-Fos, and CBP, because
they showed no significant constitutive binding, a peak of
recruitment at 1 hr, and an almost complete removal from pro-
moters and enhancers after 6 hr of stimulation (Figures 6A and
6B). Group 2 consists of JunD and c-Jun, which showed consti-
tutive binding that was increased after 1 hr of IL-1 treatment and
incomplete removal from chromatin at later time points (Figures
6A and 6B). Group 3 contains ATF2 and FRA1, which showed
constitutive binding that was further increased with a delayed
kinetics at 3 hr of stimulation and also incomplete removal from
promoters and enhancers after prolonged IL-1 stimulation (Fig-
ures 6A and 6B). Additional experiments showed that P(S5)-Pol
II binding most closely mirrored the sharp recruitment profile of
p65 and occurred only at IL8 and CXCL2 promoters but not at
the enhancers (Figures 6A and 6B). Interestingly, p65 recruitment
was already detectable between 10 and 20min at IL8 andCXCL2
promoters and occurred with a delay at both chemokine en-
hancers (Figures 6A and 6B). In contrast, there was no difference
in the kinetics of p65 removal from the IL8 andCXCL2promoters/
enhancers (Figures 6A and 6B). Although this effect is relatively
small, this observation would be consistent with a model where
p65 binds first to the promoter regions of both chemokine loci
and subsequently coordinates additional formation of the pro-
moter/enhancer platforms, perhaps by CBP-mediated progres-
sive acetylation at H3K27. Then, we asked which of these events
were under control of TAK1. As shown in Figures 6C and 6D, 5Z-
7-oxozeaenol blocked in all cases the IL-1-inducible recruitment
of p65 and AP-1 factors and had little if any effect on constitutive
chromatin binding of these transcription factors. To investigate a
possible role of p65 for IL-1-triggered recruitment of AP-1 family
members, p65 knockdown cells were used. Between 15 and
60 min of IL-1-stimulation, p65 knockdown did not affect activa-
tion of p38, JNK, or the total expression levels of c-Fos and JunD,
two AP-1 proteins that bind to promoters and enhancers of IL8
andCXCL2 loci in KB and HeLa cells (Figure 7A). Like in KB cells,
c-Fos protein expression and chromatin loading was highly IL-1-
inducible,whereas theconstitutively expressedJunDprotein dis-
played basal but also IL-1-inducible recruitment to the IL8 and
CXCL2 loci (Figures 7A and 7B). Knockdown of p65 preventedCethe inducible recruitment of c-Fos, JunD, CBP, and P(S5)-Pol II
to the IL8 and CXCL2 loci (Figure 7B). In addition, interference
with p65 expression also resulted in impaired recruitment of its
heterodimeric partner p50 NF-kB (Figure 7B). In contrast, knock-
down of c-Fos or JunD, which was sufficient to suppress their
own chromatin recruitment had no effect on inducible p65 bind-
ing (Figure S7C), thus identifying p65 as a master transcription
factor of inflammatory enhancer activation. Furthermore, knock-
down of c-Fos or JunD resulted only in slightly impaired IL-1-
induced expression of IL8 or CXCL2 mRNAs (Figure 7C). These
data indicate that p65 is essential for the assembly of
TF collectives andadditional cofactors at both promoters and en-
hancers. The data obtained by the quantitative ChIP-PCR
analyses of the IL8 andCXCL2 genomic loci in the various knock-
down cells or in cells treated with kinase inhibitors were then
normalized and integrated to obtain a comprehensive view on
the IL-1-triggered signaling events at the chromatin level.
These summarizing analyses corroborate the conclusion that
IL-1-inducible H3K27ac is primarily regulated through the
TAK1-IKK2-p65 pathway, whereas AP-1 proteins such as c-
Fos and JunD have little effect (Figures 7D and 7E). Altogether,
these data reveal the fundamental role of the TAK1-IKK2-p65
pathway in orchestrating the assembly of promoter and enhancer
complexes and the accompanying H3K27ac modifications for
driving maximal mRNA expression of IL-1-induced genes.
DISCUSSION
Sterile, cytokine-driven inflammation is the underlying cause of
numerous diseases such as rheumatoid arthritis, psoriasis, or
gout (Chen and Nun˜ez, 2010). It has long been known that de-
regulated gene expression is a hallmark of all inflammatory pro-
cesses (Bhatt et al., 2012; Medzhitov and Horng, 2009; Hao and
Baltimore, 2009). The receptors and cytosolic pathways orches-
trating inflammatory gene expression have been studied in
considerable detail (Gaestel et al., 2009). However, how these
pathways transduce their information to chromatin is not well
understood.
Here, we identify a large number of IL-1-inducible enhancers
and their signal-mediated regulation in epithelial cells. The start-
ing point of our study was the discovery of two enhancer regions
flanking a cluster of four highly regulatedCXC chemokine genes.
In accordance with concurrent studies, we classified these en-
hancers as active genomic regions due to the simultaneous
occurrence of H3K4me1 and H3K27ac marks and to the pres-
ence of CBP (Calo and Wysocka, 2013). However, there were
also specific features, in particular, the further, IL-1-dependent
upregulation of H3K27ac but not H3K4me1 and the rapid, regu-
lated recruitment of the p65 NF-kB subunit. At the genome-wide
level, we report more than 45,000 mostly intergenic p65 binding
sites. So far, p65 binding events have been mapped in several
other cell types in response to TNF-a or LPS. Using lower reso-
lution ChIP-Chip or ChIP-Pet techniques, 348 or 489 promoter-
near p65 sites and 209 sites distributed at intergenic regions
across chromosome 22 were reported (Lim et al., 2007;
Schreiber et al., 2006; Martone et al., 2003). In more recent
deep sequencing studies, the numbers of p65 peaks ranged
from 12,250 (dendritic cells) to 20,733 (A549 cells) (Jin et al.,ll Reports 10, 726–739, February 10, 2015 ª2015 The Authors 735
Figure 7. p65 Is Required for Recruitment of AP-1 Factors to Enhancers and Promoters
(A–C) HeLa cells were transfected with plasmids directing the expression of shRNAs targeting p65 (shp65), JunD (shJunD), c-Fos (shFos), or with empty pSuper-
Puro (vector) as indicated. After 2 day selection in puromycin, cells were stimulated with IL-1 for 1 hr or were left untreated. (A) Activation of NF-kB, JNK, and p38
(legend continued on next page)
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2013; Yang et al., 2013; Xing et al., 2013; Garber et al., 2012; Jin
et al., 2011; Kasowski et al., 2010). Collectively, these data
confirm initial estimates that occupied p65 NF-kB sites are within
a range of four orders of magnitude (Natoli et al., 2005). Thus, in
these conditions less than 20% of the 300,000 kB consensus
motifs in the human genome are occupied by p65 (Jin et al.,
2011). Our study describes one of the largest arrays of p65 sites
currently available. The majority of p65 binding events occur
constitutively in line with various studies reporting constitutively
occurring nuclear p65 protein (Adli and Baldwin, 2006; Nelson
et al., 2004; Birbach et al., 2002). Accordingly, a recent study
mapped >20,000 constitutive and mainly intergenic p65 peaks
in transformed B cells (Zhao et al., 2014). Our subcellular frac-
tionation and high-resolution mapping experiments indicate
that most of the nuclear p65 protein is contained within the sol-
uble fraction and only small amounts are stably associated with
chromatin. These observations indicate that not only the nuclear
entry of p65 is a regulated event, but also the balance between
free nuclear versus chromatin-associated p65. These mecha-
nisms are likely to be locus specific and accordingly the p65 pro-
tein resides at constitutively occupied and IL-1-induced sites.
The majority of p65 binding events occur at intergenic regions
devoid of RNA polymerase II because two-thirds of 1,264 IL-1-
regulated p65 peaks were localized >20 kb upstream of the
next annotated gene. By combining these data with further
ChIP-seq and mRNA expression analyses, we identified 410
enhancers, which were regulated by IL-1 at the level of p65
recruitment, H3K27 acetylation, enhancer width, and mRNA
expression of neighboring genes. Thus, the genome-wide results
resemble all of the features of the CXC chemokine cluster shown
in Figure 1 and suggest that this group of enhancers has general
relevance for IL-1-mediated gene regulation. Enhancers that
display TNF-a-inducible H3K27ac have also been noted recently
in fibroblasts, and it will be interesting to analyze if they overlap
with class II enhancers described in our study (Jin et al., 2013).
Because the correlation of enhancer marks with p65 occupancy
does not prove the functional relevance of the enhancer struc-
tures for gene expression, we used kinase inhibitor and p65
knockdown experiments to reveal an essential role for the p65
subunit in enhancer activation and subsequent mRNA transcrip-
tion at the CXC locus. These data provide strong evidence for
p65 as a master regulator of IL-1-inducible H3K27ac. Occur-MAPK pathways or expression of NF-kB subunits or AP-1 proteins was analyze
immunoblotting of whole-cell extracts using the indicated antibodies. Equal load
experiments. (B) Control cells or p65 knockdown cells (shp65) were stimulated fo
using the indicated antibodies with primers covering the promoter or enhancer reg
in Figure 5B. The bars show themean enrichment (% input) ±SEM from at least two
cells were stimulated with IL-1 for 1 hr or were left untreated. Knockdowns were
determined by RT-qPCR (bottom). Shown are mean fold changes ± SEM from th
(D) ChIP-PCR data covering the IL8 and CXCL2 enhancer and promoter regions
pooled, measurements of H3K27ac and H3K4me1 were normalized to H3 levels,
transfected control cells. One data point for the CXCL2 locus shown in Figure S7C
misleadingly high ratio values. Shown are themean changes ±SEM from ten (vect
experiments.
(E) Changes in H3 modifications were calculated as in (D) for all experiments us
(bottom) and in Figure S6A. Shown are the mean changes ± SEM from combin
inhibitor.
See also Figure S7.
Cerence of H3K4me1 was independent of p65, suggesting that
IL-1-regulated signaling pathways recognize genomic regions
that are already premarked as enhancers.
Themolecular events connecting cytosolic signaling pathways
with enhancer regulation are still incompletely understood (Calo
and Wysocka, 2013; Pennacchio et al., 2013). Here, we identify
the kinase TAK1 and its downstream kinase IKK2 as important
regulators allowing cytokine-triggered chromatin modification.
TAK1 and also IKK2 are essential components of the canonical
NF-kB pathway (Ha¨cker and Karin, 2006). Inhibition of TAK1
or IKK2 kinase activities with specific small molecule inhibitors
suppressed IL-1-induced p65 recruitment and H3K27ac at class
II enhancers and accordingly also the IL-1-gene response. In-
depth quantitative ChIP-PCR analyses of theCXC loci confirmed
the genome-wide data and together with the p65 knockdown
effects on enhancer acetylation place a TAK1-IKK2-p65 pathway
at the center of signal-mediated enhancer acetylation.
However, TAK1 inhibition will also interfere with IL-1-triggered
MAPK signaling (Ninomiya-Tsuji et al., 1999). At the level of chro-
matin, 5Z-7-oxozeaenol impaired the IL-1-inducible and (to a
lesser extent) the basal enhancer recruitment of c-Jun, JunD,
JunB, ATF2, c-Fos, and FRA1 to theCXC chemokine locus. These
data define a transcription factor collective that employs TAK1-
derived signals to assemble at inflammatory enhancers. Motif
searches within IL-1-inducible class II enhancers suggest that
they are enriched for NF-kB and AP-1 sites, whereby themotif ar-
rangements; i.e., their relative order, orientation, and spacing, are
relatively flexible (M.K. and M.B., unpublished data). Our experi-
ments identify p65 as an essential component governing further
TFbinding events to theseciselements, because its absencepre-
cludes c-Fos and JunD binding as well as CBP recruitment and
H3K27 acetylation. In contrast, suppression of JunD and c-Fos
expression had little effect on p65-mediated enhancer activation,
thus identifying a hierarchy among the transcription factors.
Because AP-1 subunits do not serve as pioneering transcription
factors, they presumably exert further functions such as the reso-
lution of enhancer activation or shaping the kinetics of IL-1-medi-
ated gene expression. Thus, the relative contribution of the indi-
vidual AP-1 subunits downstream of TAK1 to enhancer activity
and downstream gene activation remains to be determined.
These results raise the question on the mechanisms employed
by the enhancer complexes to support inflammatory gened in p65 knockdown or control cells stimulated for various times with IL-1 by
ing was confirmed using antibodies against tubulin. Shown is one out of three
r 1 hr with IL-1 or were left untreated. ChIP-PCR experiments were performed
ions of the IL8 locus (top) or theCXCL2 locus (bottom) as schematically shown
experiments performed in duplicates. (C) c-Fos or JunD knockdown or control
validated by immunoblotting (top) and mRNA expression of IL8 or CXCL2 was
ree (JunD) or two (c-Fos) independent experiments performed in duplicates.
from all HeLa cell knockdown experiments (Figures 5C, S6C, and S7C) were
and IL-1-regulated changes were calculated as fold changes relative to vector-
(shFos ChIP-PCR 3) was omitted due to very low H3 signals, which resulted in
or controls), three (shTAK1 and shJunD), or two (shp65 and shFos) independent
ing TAK1 (5Z) or IKK2 (PHA-408) inhibitors in KB cells as shown in Figure 5C
ing four independent experiments for controls and two experiments for each
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expression. Some enhancers transcribe regulatory RNAs that
promote transcription from downstream protein-coding genes
(Li et al., 2013; Simonatto et al., 2013). However, based on
RNA-seq we did not detect RNA at the enhancers, and we also
found only spurious amounts of RNA Pol II associated with the
IL8 and CXCL2 enhancers. The enhancers of these two genes
are located more than 400 kb apart, and their function might be
to promote physical interactions by chromatin loopings. They
may extend to the promoter regions of individual genes within
the cluster, as suggested by the observation that the NF-kB
and AP-1 TF collective is also found at the IL8 and CXCL2 pro-
moters. Additionally, they may contact regions on other chromo-
somes to form regulatory enhancer archipelagosbymultiple long-
range chromatin interactions (Spitz and Furlong, 2012; Montavon
et al., 2011). Such inflammatory enhancer landscapesmay syner-
gize to provide the very robust and synchronized expression of
canonical inflammatory genes as shown in Figure S1. Indeed, a
recent study identified over a million long-range chromatin inter-
actions at 5–10 kb resolution in TNF-stimulated cells (Jin et al.,
2013). Thus, our data provide important clues for further studies
directed toward the identification of signals that determine the
3D architecture of chromatin during IL-1-driven inflammation.
In summary, we report a time-dependent IL-1-inducible for-
mation of enhancers, which can be viewed as an epigenetic
amplifying or feedforward mechanism by which cells achieve
the particularly strong and rapid gene expression responses
that are typically observed in cytokine-stimulated cells. In the
future, it will therefore be interesting to examine possible poly-
morphisms within the DNA-binding motifs or in the TF collective
that we have identified within the enhancer peaks and subse-
quent alterations in the enhancer architecture. These changes
could also account for chronically ongoing expression of proin-
flammatory genes in inflammatory diseases.
EXPERIMENTAL PROCEDURES
Cell Lines and Materials
HeLa and KB human epithelial carcinoma cell lines have been described
(Handschick et al., 2014; Hoffmann et al., 2005). Recombinant human IL-1a
was used at 10 ng/ml in all experiments. 5Z-7-oxozeaenol was from Tocris
Bioscience; PHA-408 was from Axon Medchem.
Plasmids and Transfections of Cell Lines
shRNA constructs for p65 (Handschick et al., 2014), JunD, c-Fos, and TAK1
were prepared in pSuper-Puro or pLKO.1 (shTAK1) backbones. HeLa cells
were transiently transfected by the calcium phosphate method and were
selected for 48–96 hr with 1 mg/ml puromycin.
Cell Lysis and Immunodetection of Proteins
Whole-cell extracts, cytosolic, soluble nuclear, and insoluble nuclear extracts
were prepared and used for immunoblotting as described (Handschick et al.,
2014).
Gene Expression Measurements
All mRNAmeasurements were performed by RT-qPCR, by Agilent microarrays
or by RNA-seq with total RNA as described (Handschick et al., 2014).
Chromatin Immunoprecipitation and PCR
ChIPwas performed from formaldehyde crosslinked cells, andDNAwas quan-
tified by real-time PCR with SYBR Green as described previously in detail
(Handschick et al., 2014).738 Cell Reports 10, 726–739, February 10, 2015 ª2015 The AuthorsDeep Sequencing of Nucleic Acids
Sequencing libraries were prepared and analyzed using Illumina reagents and
an Illumina HiSeq2500 machine.
ChIP-Seq, RNA-Seq, andMicroarray Analyses andData Visualization
Conversion and alignment of ChIP-seq and RNA-seq reads to the hg19 refer-
ence genome followed standard procedures. Visualization of binding profiles,
enhancer analyses, motif searches, and data analyses of microarray experi-
ments are described in the Supplemental Information. Statistics for all meta-
analyses were calculated using the Wilcoxon signed rank test. In all box plots,
black lines indicate medians, boxes the lower and upper quartiles (25% and
75%), and whiskers the minimum and maximum values.
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